Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEBUFLAG: FLAMOD in Healthy Subjects
NCT06681402Phase 1Completed
- Sponsor
- Inserm
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in pneumonia comparing FLAMOD with Placebo (2 arms). Primary endpoint: Safety and tolerability of a single administration dose of FLAMOD at 2 weeks. Started Apr 2025; status: completed.
02
Drugs
FLAMOD
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT06681402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681402.